No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients

BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week tre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Gastroenterol Hepatol
Autors principals: Marcus, Julia L., Hurley, Leo B., Chamberland, Scott, Champsi, Jamila H., Gittleman, Laura C., Korn, Daniel G., Lai, Jennifer B., Lam, Jennifer O., Pauly, Mary Patricia, Quesenberry, Charles P., Ready, Joanna, Saxena, Varun, Seo, Suk, Witt, David J., Silverberg, Michael J.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962408/
https://ncbi.nlm.nih.gov/pubmed/29535057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.03.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars